MEDICINOVA, INC. a Delaware corporation and AMERICAN STOCK TRANSFER & TRUST COMPANY a New York corporation Rights AgentRights Agreement • November 29th, 2006 • Medicinova Inc • Pharmaceutical preparations • Delaware
THIS RIGHTS AGREEMENT (this “Agreement”) is dated as of November 24, 2006, between MEDICINOVA, INC., a Delaware corporation (the “Company”), and AMERICAN STOCK TRANSFER & TRUST COMPANY, a New York corporation (the “Rights Agent”).
MEDICINOVA, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • August 23rd, 2019 • Medicinova Inc • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • August 21st, 2012 • Medicinova Inc • Pharmaceutical preparations • Illinois
COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of August 20, 2012 by and between MEDICINOVA, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 21st, 2012 • Medicinova Inc • Pharmaceutical preparations • Illinois
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 20, 2012, by and between MEDICINOVA, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
MEDICINOVA, INC. INDEMNITY AGREEMENTIndemnification Agreement • March 28th, 2013 • Medicinova Inc • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between MEDICINOVA, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
MEDICINOVA, INC. Common Stock (par value $0.001 per share) At-the-Market Issuance Sales AgreementAt-the-Market Issuance Sales Agreement • May 22nd, 2015 • Medicinova Inc • Pharmaceutical preparations • New York
MediciNova, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
THE PLAZA AT LA JOLLA VILLAGE SMITH BARNEY TOWER SAN DIEGO, CALIFORNIA OFFICE LEASE AGREEMENT BETWEEN CA-LA JOLLA II LIMITED PARTNERSHIP, a Delaware limited partnership (“LANDLORD”) AND MEDICINOVA, INC., a Delaware corporation (“TENANT”)Office Lease Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • California
THIS OFFICE LEASE AGREEMENT (the “Lease”) is made and entered into as of the 28th day of January 2004, by and between CA-LA JOLLA II LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”) and MEDICINOVA, INC., a Delaware corporation (“Tenant”). The following exhibits and attachments are incorporated into and made a part of the Lease: Exhibit A (Outline and Location of Premises), Exhibit B (Expenses and Taxes), Exhibit C (Work Letter), Exhibit D (Commencement Letter), Exhibit E (Building Rules and Regulations). Exhibit F (Additional Provisions) and Exhibit G (Parking Agreement).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 10th, 2013 • Medicinova Inc • Pharmaceutical preparations • California
This Securities Purchase Agreement (this “Agreement”) is dated as of May 9, 2013 by and among MediciNova, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule A hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).
FORM OF MEDICINOVA, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • September 1st, 2005 • Medicinova Inc • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is entered into as of , 200 (the “Effective Date”), by and between MEDICINOVA, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
MEDICINOVA, INC. 2,750,000 Units Each Unit consisting of One Share of Common Stock and a Warrant to Purchase One Share of Common Stock UNDERWRITING AGREEMENT March 23, 2011Underwriting Agreement • March 24th, 2011 • Medicinova Inc • Pharmaceutical preparations • New York
MEDICINOVA, INC. 4,419,890 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 8th, 2018 • Medicinova Inc • Pharmaceutical preparations • New York
MEDICINOVA, INC., a Delaware corporation (the “Company”), proposes to issue and sell to Ladenburg Thalmann & Co. Inc. (the “Representative”) and the other underwriters listed on Schedule I hereto (collectively, with the Representative, the “Underwriters”), pursuant to and in accordance with the terms and conditions of this underwriting agreement (the “Agreement”), an aggregate of 4,419,890 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”).
SEVERANCE PROTECTION AGREEMENTSeverance Protection Agreement • August 13th, 2014 • Medicinova Inc • Pharmaceutical preparations • Delaware
SEVERANCE PROTECTION AGREEMENT, dated July 14, 2014, by and between MediciNova, Inc., a Delaware corporation (the “Company”), and Geoffrey O’Brien (the “Executive”).
MEDICINOVA, INC. and , As Warrant Agent FORM OF PREFERRED STOCK WARRANT AGREEMENT Dated As OfWarrant Agreement • November 16th, 2012 • Medicinova Inc • Pharmaceutical preparations • New York
PREFERRED STOCK WARRANT AGREEMENT (the “Agreement”), dated as of between MEDICINOVA, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
EXECUTIVE EMPLOYMENT AGREEMENT (Michael E. Kalafer, M.D.)Executive Employment Agreement • July 7th, 2008 • Medicinova Inc • Pharmaceutical preparations • California
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of July 3, 2008 (the “Effective Date”) by and between MEDICINOVA, INC, a Delaware corporation (“MediciNova”), and Michael E. Kalafer, M.D. (“Executive”), with reference to the following facts:
MEDICINOVA, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • January 29th, 2007 • Medicinova Inc • Pharmaceutical preparations • New York
INDENTURE between MEDICINOVA, INC. as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in SeriesIndenture • September 22nd, 2017 • Medicinova Inc • Pharmaceutical preparations • New York
INDENTURE, dated as of , 20 , between MEDICINOVA, INC., a Delaware corporation, as Issuer (the “Company”), having its principal office at 4275 Executive Square, Suite 650, La Jolla, California 92037, and [TRUSTEE], a New York banking corporation, as Trustee (the “Trustee”).
LICENSE AGREEMENTLicense Agreement • January 6th, 2005 • Medicinova Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) dated as of December 8, 2004 (“Effective Date”), is entered into between MediciNova, Inc., a Delaware corporation (“MN”) having a place of business located at 4350 La Jolla Village Drive, Ste 950, San Diego, California 92122, U.S.A., and Mitsubishi Pharma Corporation, a Japanese corporation (“MPC”), having a place of business located at 6-9, Hiranomach 2-chome, Chuo-ku, Osaka 541-0046, Japan.
Re: Account Number (the “Account”) ADDENDUM TO CREDIT LINE AGREEMENTCredit Line Agreement • January 21st, 2009 • Medicinova Inc • Pharmaceutical preparations
The attached “Credit Line Agreement” sets forth certain terms related to the extension of credit by UBS Bank USA (“The “Bank”) with respect to certain assets held through the above-referenced non-discretionary corporate cash management Account with UBS Financial Services Inc. (the “Firm”). The party signing this Addendum as Client where indicated below (the “Client”) understands and agrees that, notwithstanding anything to the contrary contained in either the Credit Line Agreement (including without limitation Section 19 of the Credit Line Agreement) or the existing Corporate Cash Management Account Agreement applicable to the Account, as amended from time to time (the “Account Agreement”), the terms of the Credit Line Agreement supplement, but do not replace, the existing Account Agreement as follows: (i) the terms of the Credit Line Agreement (as amended from time to time, in accordance with its terms) shall govern with respect to any matters, issues or disputes related directly to,
MEDICINOVA, INC. and , As Warrant Agent FORM OF DEBT SECURITIES WARRANT AGREEMENT Dated As OfWarrant Agreement • November 16th, 2012 • Medicinova Inc • Pharmaceutical preparations • New York
DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between MEDICINOVA, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
LICENSE AGREEMENTLicense Agreement • January 6th, 2005 • Medicinova Inc • Pharmaceutical preparations • Delaware
THIS LICENSE AGREEMENT (this “Agreement”) dated as of October 22, 2004 (the “Effective Date”), is entered into between MediciNova, Inc., a Delaware corporation (“MN”) having a place of business located at 4350 La Jolla Village Drive, Suite 950, San Diego, California 92122, U.S.A., and Kyorin Pharmaceutical Co., Ltd., a Japanese corporation (“KR”), having a place of business located at 5, Kanda Surugadai 2-chome, Chiyoda-ku, Tokyo 101-8311, Japan.
Each of the undersigned agrees that (i) the statement on Schedule 13D relating to the Common Stock of Medicinova, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13D will, unless...Joint Filing Agreement • February 13th, 2006 • Medicinova Inc • Pharmaceutical preparations
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
LEASE BETWEEN THE IRVINE COMPANY LLC AND MEDICINOVA, INC.Lease • July 23rd, 2021 • Medicinova Inc • Pharmaceutical preparations • California
THIS LEASE is made as of July 20, 2021 , by and between THE IRVINE COMPANY LLC, a Delaware limited liability company, hereafter called “Landlord,” and MEDICINOVA, INC., a Delaware corporation, hereafter called “Tenant.”
LICENSE AGREEMENTLicense Agreement • November 2nd, 2006 • Medicinova Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (hereinafter referred to as “Agreement”) dated as of October 31, 2006 (hereinafter referred to as “Effective Date”), is entered into between MediciNova, Inc., a Delaware corporation having a place of business located at 4350 La Jolla Village Drive, Ste 950, San Diego, California 92122, U.S.A. (hereinafter referred to as “MN”), and Meiji Seika Kaisha, Ltd., a Japanese corporation having its principal business place at 4-16, Kyobashi 2-chome, Chuo-ku, Tokyo 104-8002, Japan (hereinafter referred to as “MS”).
FORM OF GREEN SHOE OPTION AGREEMENTGreen Shoe Option Agreement • January 27th, 2005 • Medicinova Inc • Pharmaceutical preparations
RELATING TO GREEN SHOE OPTION AGREEMENT (this “Agreement”) is made and entered into in Tokyo, Japan, as of , 2005 by and between MediciNova, Inc. (the “Company”) and Daiwa Securities SMBC Co. Ltd. (“Daiwa Securities SMBC”) acting as representative of the Underwriters (hereinafter defined) in connection with the granting, exercise of, and the issuance of shares (the “Optional Shares”) pursuant to, the green shoe option (the “Green Shoe Option”) set forth under Article 3 of the “MediciNova, Inc. 30,000,000 Shares of Common Stock Subscription Agreement” (the “Subscription Agreement”) entered into by and between the Company and Daiwa Securities SMBC as representative of the underwriters (the “Underwriters”) named therein and dated the date hereof in connection with the subscription and offering (the “Offering”) in Japan of 30,000,000 shares of common stock of the Company and the secondary offering by Daiwa Securities SMBC in Japan of 4,500,000 shares (the “Secondary Offering Shares by mean
ContractStock Purchase Warrant • October 1st, 2004 • Medicinova Inc • California
THIS WARRANT WAS ORIGINALLY ISSUED EFFECTIVE SEPTEMBER 26, 2000 AND SUCH ISSUANCE WAS NOT REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY APPLICABLE STATE SECURITIES LAWS. CONSEQUENTLY, THIS WARRANT MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.
MEDICINOVA, INC. Common Stock EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • October 16th, 2013 • Medicinova Inc • Pharmaceutical preparations • New York
EXECUTIVE EMPLOYMENT AGREEMENT Michael CoffeeExecutive Employment Agreement • June 16th, 2010 • Medicinova Inc • Pharmaceutical preparations • Delaware
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of June 14, 2010 by and between MEDICINOVA, INC, a Delaware corporation (“MediciNova”), and Michael Coffee (“Executive”), with reference to the following facts:
Master Services AgreementMaster Services Agreement • November 24th, 2004 • Medicinova Inc • Pharmaceutical preparations • California
** CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
ENGAGEMENT AGREEMENTEngagement Agreement • April 3rd, 2015 • Medicinova Inc • Pharmaceutical preparations
SUBLEASESublease • March 1st, 2013 • Medicinova Inc • Pharmaceutical preparations • California
This Sublease, dated as of this 27th day of February, 2013, between Denali Advisors LLC, a Delaware limited liability company (“Sublandlord”) and MediciNova, Inc., a Delaware corporation (“Subtenant”).
FIFTH AMENDMENTLease Agreement • July 12th, 2011 • Medicinova Inc • Pharmaceutical preparations
THIS FIFTH AMENDMENT (the “Amendment”) is made and entered into as of July 6, 2011, by and between 4350 LA JOLLA VILLAGE LLC, a Delaware limited liability company, (“Landlord”) and MEDICINOVA, INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO SEVERANCE PROTECTION AGREEMENTSeverance Protection Agreement • January 4th, 2011 • Medicinova Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO SEVERANCE PROTECTION AGREEMENT (the “Amendment”), dated December , 2010, by and between MediciNova, Inc., a Delaware corporation (the “Company”), and (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 1st, 2004 • Medicinova Inc • California
THIS AGREEMENT is made effective as of 26th day of September, 2003 (hereinafter referred to as the “Effective Date”), by and between MEDICINOVA (hereinafter referred to as “MEDICINOVA”), a Delaware corporation, whose principal offices are located at 4370 La Jolla Village Drive, Suite 400, San Diego, CA 92122, U.S.A. and TAKASHI KIYOIZUMI, M.D., Ph.D., Sc.M., who resides at 17231 Holly Leaf Court, San Diego, CA 92127, U.S.A. (hereinafter referred to as “CEO”).
SEPARATION AGREEMENT AND RELEASESeparation Agreement • July 2nd, 2009 • Medicinova Inc • Pharmaceutical preparations • California
This Separation Agreement and Release (this “Agreement”) is entered into by and between Richard E. Gammans, Ph.D., (“Gammans”) and MediciNova, Inc. a Delaware corporation (the “Company”), with regard to the following:
MEDICINOVA, INC. and , As Warrant Agent FORM OF COMMON STOCK WARRANT AGREEMENT Dated As OfWarrant Agreement • November 16th, 2012 • Medicinova Inc • Pharmaceutical preparations • New York
COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between MEDICINOVA, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
